Breaking Barriers: FDA Approves IMCIVREE (Setmelanotide) for Patients as Young as 2 Years Old
Breaking News: FDA Approves Expanded Indication for IMCIVREE® to Include Children as Young as 2 Years Old Redefining Treatment for Rare Neuroendocrine Diseases By: Medical Correspondent In a groundbreaking development, Rhythm Pharmaceuticals, Inc. has received approval from the U.S. Food and Drug Administration (FDA) to expand the indication for IMCIVREE® (setmelanotide) to include children as…